BENDAMUSTINE HYDROCHLORIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2008)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 981Y8SX18M
Parent Compound: BENDAMUSTINE

Structure
InChI Key ZHSKUOZOLHMKEA-UHFFFAOYSA-N
Smile Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21
InChI
InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H22Cl3N3O2
Molecular Weight 394.73
AlogP 3.26
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 9.0
Polar Surface Area 58.36
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 23.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR DNA inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lymphoma, Non-Hodgkin 4 D008228 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Astrocytoma 2 D001254 ClinicalTrials
Oligodendroglioma 2 D009837 ClinicalTrials
Gliosarcoma 2 D018316 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Lung Neoplasms 2 D008175 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Amyloidosis, Familial 2 D028226 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Hematologic Neoplasms 1 D019337 ClinicalTrials

Related Entries

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
11.82
Blood and lymphatic system disorders
9.87
Infections and infestations
9.19
Injury, poisoning and procedural complications
8.04
Respiratory, thoracic and mediastinal disorders
7.32
Gastrointestinal disorders
6.37
Vascular disorders
6.08
Nervous system disorders
5.78
Skin and subcutaneous tissue disorders
5.6
Investigations
5.48
Immune system disorders
4.42
Cardiac disorders
4.18
Metabolism and nutrition disorders
3.18
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.16
Renal and urinary disorders
2.2

Cross References

Resources Reference
ChEMBL CHEMBL1201734
EPA CompTox DTXSID40188912
FDA SRS 981Y8SX18M
PubChem 77082
SureChEMBL SCHEMBL18843
CONTENTS